Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients

Hannah L Pellkofer; Lena Armbruster; Rainer Linke; Friedrich Schumm; Raymond Voltz

doi:10.1016/j.jneuroim.2009.09.017

Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients

J Neuroimmunol. 2009 Dec 10;217(1-2):90-4. doi: 10.1016/j.jneuroim.2009.09.017. Epub 2009 Oct 14.

Authors

Hannah L Pellkofer¹, Lena Armbruster, Rainer Linke, Friedrich Schumm, Raymond Voltz

Affiliation

¹ Institute for Clinical Neuroimmunology, Ludwig Maximilians University of Munich, 81377 Munich, Germany. [email protected]

PMID: 19833394
DOI: 10.1016/j.jneuroim.2009.09.017

Abstract

In about 40% of patients LEMS is not a paraneoplastic phenomenon (NT-LEMS). Several clinical aspects important to these patients remain open, especially the question when a LEMS can definitely be diagnosed as NT-LEMS. Here we describe a series of 25 German NT-LEMS patients regarding their clinical characteristics, duration of symptoms, value of serological markers, paraneoplastic antibodies and FDG-PET/CT. Furthermore, we discuss the current diagnostic criteria of NT-LEMS.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Child
Diagnosis, Differential
Female
Fluorodeoxyglucose F18
Germany
Humans
Lambert-Eaton Myasthenic Syndrome / diagnosis*
Lambert-Eaton Myasthenic Syndrome / diagnostic imaging
Lambert-Eaton Myasthenic Syndrome / physiopathology
Lambert-Eaton Myasthenic Syndrome / therapy*
Male
Middle Aged
Phosphopyruvate Hydratase / metabolism
Positron-Emission Tomography / methods
Young Adult

Substances

Fluorodeoxyglucose F18
Phosphopyruvate Hydratase